ClinicalTrials.gg
CompletedNCT03648450Updated Oct 19, 2026Results posted

Feasibility and Acceptability of the Propeller Monitoring System in Children With Persistent Asthma

An observational study in Asthma, sponsored by Connecticut Children's Medical Center. Completed at 1 site in United States. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Connecticut Children's Medical Center · Observational

How we know

Updated Oct 19, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
42
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Enrollment
242nd of 330
42 · median 112
Started
2020
with 48 others
Observational
335 of 1,696
34 open now
Registered
1,253rd of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 242nd largest by enrollment of the 330 observational ones that give a count, is one of 49 that started in 2020, is one of 335 observational ones, and was the 1,253rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The main hypothesis of this study is to see if children and adolescents with poorly controlled asthma will find the Propeller electronic monitoring device is feasible and acceptable, and will result in improved medication adherence and asthma control. Preliminary studies indicate that Propeller can improve medication adherence rates in children with asthma and reduce the number of days of reliever medication used. It also has been shown to reduce missed days of school and hospitalizations due to asthma exacerbations. The Propeller device is a sensor that fits over inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication. It also records use of the controller and rescue inhalers, allowing for parents, physicians, and patients to get a fuller and more accurate picture of their adherence to treatment and severity of disease. With improved adherence, asthma control should improve, resulting in a decreased costs and use of services.

Read the detailed description

This study is a prospective cohort study using a pre-/post-design.

The target population consists of children and adolescents 10-18 years old making an ED visit or admitted to the hospital at Connecticut Children's Medical Center for an asthma exacerbation.

All patients will receive two Propeller devices (for controller and rescue inhalers), an App for their smartphone, and a free Propeller subscription, which provides access support and services, and hardware and software updates. Only the children and adolescents involved with the study will have the app on their phone. The parents will not put the Propeller app on their phone. Families will be asked to share the study information with their primary care provider and will be provided with an introductory letter to bring to the provider, if they so choose.

Data collection will begin at enrollment and will continue through the three-month follow-up period. Propeller provides the option of continuous monitoring and data collection beyond study cessation.

Data uploads to the portal occur automatically for patients and caregivers who have installed the Propeller App on their smartphone. Additionally, patients' primary-care providers will receive a password allowing them to track and access participants' dashboard. Patients will bring a letter to their primary-care provider explaining that they are part of a study of Propeller's device, and receive instructions on how to view the dashboard and adherence data.

At enrollment, participants and parents will complete the Test of Adherence to Inhalers (TAI), Asthma Control Test (ACT) and PedsQL, along with providing baseline medical history/asthma history data and sociodemographic. The TAI, ACT and PedsQL surveys will again be completed one and three months post enrollment information. Additionally, participants will answer an adapted AMDAT survey that will be used to provide acceptability data about the Propeller device.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population consists of children and adolescents 4-18 years old making an ED visit or admitted to the hospital at Connecticut Children's Medical Center for an asthma exacerbation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children in the ED or inpatient setting presenting with an asthma exacerbation between 4-18 years old
  2. History of persistent asthma (defined as prescribed a controller medication)
  3. Both the child and primary caregiver/parent have access to a cell phone with an activated number
  4. Ability of child's parent/legal guardian to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Child or parent has no access to a personal cell phone.
  2. The child has another chronic pulmonary condition (for example, cystic fibrosis)
  3. Having any chronic condition that could affect the child's ability to participate in the study (examples: cancer, autism, or cerebral palsy)
  4. The subject has an inhaler medication besides the following, given these are the current medications compatible with the Propeller EMD.

    i. Advair HFA ii. Flovent HFA iii. QVAR HFA v. Ventolin HFA vi. ProAir HFA

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
42 participants (actual)
Patient registry
No

Groups and cohorts

  • Propeller Smart Inhaler EMD

    All enrolled participants will be given the Propeller Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.

    Other: Propeller EMD

Interventions

  • OtherPropeller EMD

    Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.

06

What researchers measure

Primary outcomes

  1. Propeller Device Use at Three Months

    Device use will be assessed by recording the number and percentage of children and adolescents still using the Propeller electronic monitoring device at 3 months following enrollment.

    Time frame: 3 months

Secondary outcomes

  1. Acceptability of the Propeller EMD as Determined by the Electronic Medical Devices Assessment Toolkit (AMDAT)

    Acceptability of the Propeller electronic monitoring device will be assessed through phone interviews and participant survey responses using the modified Adolescent Medical Devices Assessment Toolkit (AMDAT). Surveys will be administered at baseline, 1 month, and 3 months following enrollment to assess user experience, usability, and comfort using the device.

    Time frame: Baseline, 1 month, and 3 months

  2. Device Use at One Month

    Device use will be assessed by recording the number and percentage of children and adolescents using the Propeller electronic monitoring device at 1 month following enrollment.

    Time frame: 1 month

  3. Asthma Control Test (ACT) Score

    Asthma control will be measured using the Asthma Control Test (ACT), a validated questionnaire with scores ranging from 0 to 25, where higher scores indicate better asthma control. ACT will be assessed at baseline, 1 month, and 3 months after enrollment. Changes in ACT score over time will be evaluated, with a change of 3 or more points considered clinically meaningful.

    Time frame: 1 month and 3 months

  4. Medication Adherence Measured by Propeller Device

    EMD adherence was calculated for the intervention group after enrollment. Real-time inhaled corticosteroid (ICS) administration information (number of, time and date of puffs actuated) was obtained. Daily rate of adherence measured by EMD was defined as the number of actuated puffs on each day divided by the expected number of puffs, maxed at 100% to avoid overestimation due to intentional "dumping" or unintentional over-usage of medication. Average EMD adherence was calculated at 3 months.

    Time frame: 3 months

07

Results

Posted Oct 19, 2026

Participant flow

Participants were recruited from inpatient units, emergency department visits, pulmonary clinics, and primary care clinics at Connecticut Children's Medical Center. Potential participants were identified through EPIC logs and approached in person or contacted by phone. A total of 1,113 individuals were screened, of whom 42 were enrolled. Reasons for non-enrollment included ineligibility, lack of interest, inability to contact, and incompatible inhaler devices.

Participant flow — Overall Study
MilestonePropeller Smart Inhaler EMD
Started42
Completed14
Not completed28
Withdrew: Lost to follow-up8
Withdrew: Disconnected device1
Withdrew: Unable to contact1
Withdrew: Did not complete study procedures18

Outcome measures

PrimaryPropeller Device Use at Three Months

Device use will be assessed by recording the number and percentage of children and adolescents still using the Propeller electronic monitoring device at 3 months following enrollment.

Time frame:
3 months
Reported as:
Count of participants · Participants
Propeller Device Use at Three Months
ParticipantsPropeller Smart Inhaler EMD
Propeller Device Use at Three Months14
SecondaryAcceptability of the Propeller EMD as Determined by the Electronic Medical Devices Assessment Toolkit (AMDAT)

Acceptability of the Propeller electronic monitoring device will be assessed through phone interviews and participant survey responses using the modified Adolescent Medical Devices Assessment Toolkit (AMDAT). Surveys will be administered at baseline, 1 month, and 3 months following enrollment to assess user experience, usability, and comfort using the device.

Time frame:
Baseline, 1 month, and 3 months
Reported as:
Count of participants · Participants
Acceptability of the Propeller EMD as Determined by the Electronic Medical Devices Assessment Toolkit (AMDAT)
ParticipantsPropeller Smart Inhaler EMD
Participants reporting device was easy to use13
Comfortable using device in front of peers13
Would continue using device12
SecondaryDevice Use at One Month

Device use will be assessed by recording the number and percentage of children and adolescents using the Propeller electronic monitoring device at 1 month following enrollment.

Time frame:
1 month
Reported as:
Count of participants · Participants
Device Use at One Month
ParticipantsPropeller Smart Inhaler EMD
Device Use at One Month17
SecondaryAsthma Control Test (ACT) Score

Asthma control will be measured using the Asthma Control Test (ACT), a validated questionnaire with scores ranging from 0 to 25, where higher scores indicate better asthma control. ACT will be assessed at baseline, 1 month, and 3 months after enrollment. Changes in ACT score over time will be evaluated, with a change of 3 or more points considered clinically meaningful.

Time frame:
1 month and 3 months
Reported as:
Mean · Score on a scale
Asthma Control Test (ACT) Score
Score on a scalePropeller Smart Inhaler EMD
ACT Score at 1 Month19.7 (15 to 24)
ACT Score at 3 Months24 (20 to 25)
SecondaryMedication Adherence Measured by Propeller Device

EMD adherence was calculated for the intervention group after enrollment. Real-time inhaled corticosteroid (ICS) administration information (number of, time and date of puffs actuated) was obtained. Daily rate of adherence measured by EMD was defined as the number of actuated puffs on each day divided by the expected number of puffs, maxed at 100% to avoid overestimation due to intentional "dumping" or unintentional over-usage of medication. Average EMD adherence was calculated at 3 months.

Time frame:
3 months
Reported as:
Mean · percent
Medication Adherence Measured by Propeller Device
percentPropeller Smart Inhaler EMD
Medication Adherence Measured by Propeller Device54 ± 28

Adverse events

Collected over From enrollment until study completion, up to 12 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Propeller Smart Inhaler EMD0/42 (0%)0/42 (0%)0/42 (0%)

Baseline characteristics

The baseline analysis population includes all participants who were enrolled in the study (N=42). Baseline characteristics were collected at enrollment prior to initiation of the Propeller electronic monitoring device. Participants who did not complete follow-up assessments were still included in the baseline analysis.

Age, Customized
Age, Customized(Participants)Propeller Smart Inhaler EMD
Pediatric patients — Age 4-7 years19
Pediatric patients — Ages 8-11 years16
Pediatric patients — Age 12-15 years4
Pediatric patients — Age 16-18 years3
Sex: Female, Male
Sex: Female, Male(Participants)Propeller Smart Inhaler EMD
Female22
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Propeller Smart Inhaler EMD
Race/Ethnicity — Asian0
Race/Ethnicity — Black/African American12
Race/Ethnicity — Hispanic/Latino16
Race/Ethnicity — White9
Race/Ethnicity — Unknown5
Asthma control Test (ACT) Score
Asthma control Test (ACT) Score(ACT score)Propeller Smart Inhaler EMD
Mean20.7 (14 to 25)
08

Study locations

1 site
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2023, 32 months.

Results were first posted in Oct 2026, 3 years 2 months after primary completion.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 32 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 27, 2018
StartActual
Nov 1, 2020
Primary completionActual
Jul 31, 2023
CompletionActual
Aug 31, 2023
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Enrollment
50→42
Oct 19, 2026
Eligibility
Minimum age 10 Years→4 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedChildren in the ED or inpatient setting presenting with an asthma exacerbation between 104-18 years old
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRegular device usePropeller Device Use at three monthsThree MonthsTime frame: The information will be collected at three months → 3 months
Oct 19, 2026
Secondary outcomes
2 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedAcceptability of the Propeller EMD as determinedDetermined by the electronicElectronic Medical Devices Assessment Toolkit (AMDAT)Time frame: Data will be captured at enrollment, one month and three months after enrollment → Baseline, 1 month, and 3 months
  • EditedDevice useUse at one monthOne MonthTime frame: The information will be collected at one month → 1 month
  • AddedAsthma Control Test (ACT) ScoreTime frame: 1 month and 3 months
  • AddedMedication Adherence Measured by Propeller DeviceTime frame: 3 months
  • RemovedAsthma ControlTime frame: ACT will be assessed at enrollment, one month and three months.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Enrollment 50→42
    Eligibility Minimum age 10 Years→4 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedChildren in the ED or inpatient setting presenting with an asthma exacerbation between 104-18 years old
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRegular device usePropeller Device Use at three monthsThree MonthsTime frame: The information will be collected at three months → 3 months
    Secondary outcomes 2 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedAcceptability of the Propeller EMD as determinedDetermined by the electronicElectronic Medical Devices Assessment Toolkit (AMDAT)Time frame: Data will be captured at enrollment, one month and three months after enrollment → Baseline, 1 month, and 3 months
    • EditedDevice useUse at one monthOne MonthTime frame: The information will be collected at one month → 1 month
    • AddedAsthma Control Test (ACT) ScoreTime frame: 1 month and 3 months
    • AddedMedication Adherence Measured by Propeller DeviceTime frame: 3 months
    • RemovedAsthma ControlTime frame: ACT will be assessed at enrollment, one month and three months.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03648450
Lead sponsor
Connecticut Children's Medical Center
Responsible party
Jessica Hollenbach (Assistant Professor of Pediatrics, Connecticut Children's Medical Center) — Principal investigator
First posted
Aug 27, 2018
Start date
Nov 1, 2020
Primary completion
Jul 31, 2023
Completion
Aug 31, 2023
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Glenn Flores, MD
study director · Connecticut Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion